Multiple studies have shown that PD-L1 is upregulated in glioma, and PD-1/PD-L1 inhibitors in combination with other therapies significantly prolong the survival time in mice, showing positive therapeutic potential (12–15). This evidence concerns the gene CD274 and central nervous system cancer.